Meeting
2022 ASCO Annual Meeting
Resistance to anti-PD-1/anti-PD-L1: GB1211 reverses galectin-3 induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1.
Authors
Joseph Mabbitt
Galecto, Inc., Stevenage, United Kingdom
Joseph Mabbitt , James A. Roper , Robert John Slack
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2607)
DOI
10.1200/JCO.2022.40.16_suppl.2607
Abstract #
2607
Poster Bd #
262
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
First Author: Jeddeo Paul
Poster
2023 ASCO Annual Meeting
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
First Author: Antoine Italiano
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya